Opportunity Preview

Single Cell Omni-Omics

Technology

A high-throughput, multi-omics platform for single-cell profiling, integrating glycomics, proteomics, lipidomics, and metabolomics via IMS

Background

Traditional single-cell analysis methods struggle with capturing cellular heterogeneity due to bulk processing, expensive equipment, and limited multi-omics integration. Current technologies often require complex workflows, lack spatial resolution, and fail to detect low-abundance analytes effectively.

Technology Overview

Single cell omni-omics (SC-OO) is a novel microarray-based platform that enables single-cell capture and simultaneous multi-omics analysis. The system employs PDMS-stamped microwell arrays (5–30 µm diameter) for precise cell isolation, followed by processing steps such as delipidation, enzymatic treatment, and MALDI mass spectrometry imaging (MALDI-FTICR, MALDI-TOF). Key innovations include:

  • Multi-omics integration: Simultaneous profiling of N-glycans, proteomics, lipidomics, and metabolomics at the single-cell level.
  • Advanced single-cell capture: PDMS-based microarrays with antibody or lectin coatings ensure true single-cell isolation.
  • Automated ROI detection: The proprietary “SoloCell” algorithm enables rapid, targeted image analysis for mass spectrometry workflows.
  • High-throughput scalability: Processes thousands of cells in parallel, outperforming fluidics-based or droplet microfluidics methods.

Benefits

  • Comprehensive Single-Cell Profiling: Captures diverse molecular classes in a single analysis.
  • High Sensitivity & Precision: Detects low-abundance biomolecules with enhanced spatial resolution.
  • Automated & Rapid Processing: Reduces sample analysis time to ~10 minutes per cell.
  • Cost-Effective & Accessible: Uses standard substrates (e.g., epoxysilane-coated glass) with simplified workflows.
  • Versatile & Scalable: Adapts to various biomedical applications, including cancer research and drug discovery.

Applications

  • Precision Medicine & Clinical Diagnostics: Identifies disease biomarkers for personalized therapies.
  • Pharmaceutical R&D: Enhances drug screening with high-throughput single-cell analysis.
  • Multi-Omics Research Kits: Commercial potential for academic and biotech labs.
  • Mass Spectrometry Integration: Enhances existing IMS platforms with improved single-cell resolution.

Opportunity

Seeking: Licensing, commercial partnerships, and development collaborations.